Predicting pathological response of esophageal cancer to neoadjuvant chemotherapy: the implications of metabolic nodal response for personalised therapy
INTRODUCTION<br/> Only a minority of esophageal cancers demonstrates a pathological tumor response (pTR) to neoadjuvant chemotherapy (NAC). 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) is often used for restaging after NAC and to assess response. Incre...
Main Authors: | Findlay, J, Bradley, K, Mun Wang, L, Franklin, J, Teoh, E, Gleeson, F, Maynard, N, Gilies, R, Middleton, M |
---|---|
Formato: | Journal article |
Publicado: |
Society of Nuclear Medicine
2016
|
Títulos similares
-
Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer.
por: Findlay, J, et al.
Publicado: (2017) -
Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer
por: Gillies, R, et al.
Publicado: (2012) -
Metabolic response at repeat PET/CT predicts pathological response to neoadjuvant chemotherapy in oesophageal cancer.
por: Gillies, R, et al.
Publicado: (2012) -
Challenges in assessing response of oesophageal cancer to neoadjuvant therapy, and the potential of composite PET-CT and multimodal metrics.
por: Findlay, J, et al.
Publicado: (2017) -
Neutrophil-lymphocyte ratio and nodal pathologic complete response in node positive breast cancer patients undergoing neoadjuvant chemotherapy
por: M.L. Gasparri, et al.
Publicado: (2021-04-01)